Pfizer Inc.
APIXABAN FORMULATIONS

Abstract:

Compositions comprising crystalline apixaban particles having a D.sub.90 equal to or less than 89 .mu.m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.